B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Members of the B7 family have been shown to be important for regulating immune responses by providing either positive or negative costimulatory signals. The function of B7-H3 has been controversial. We show that B7-H3 is upregulated in graft-versus-host disease (GVHD) target organs, including the colon, liver, and lung. Infusion of allogeneic donor T cells into B7-H3(-/-) vs wild-type (WT) recipients resulted in increased GVHD lethality associated with increased T-cell proliferation, colonic inflammatory cytokines, and destruction of epithelial barriers. Allogeneic B7-H3(-/-) vs WT donor T cells also had increased T-cell proliferation and GVHD lethality associated with increased proliferation and cytokine secretion in the spleen, intraepithelial lymphocyte inflammatory cytokines, and intestinal permeability. Both resting and activated regulatory T cells (Tregs) lack B7-H3 messenger RNA. Consistent with these data, GVHD was augmented in recipients of B7-H3(-/-) Treg-depleted grafts. In two delayed lymphocyte infusion (DLI) models, T cells lacking B7-H3 are capable of providing graft-versus-leukemia (GVL) effects. We conclude that B7-H3 is responsible for providing a negative costimulatory signal. Our studies provide support for developing and testing new therapies directed toward the B7-H3 pathway, including approaches to augment host B7-H3 early after bone marrow transplantation to prevent GVHD and to develop potent antagonistic antibodies later after transplant to facilitate DLI-mediated GVL without GVHD complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses
Suh, W.-K., Gajewska, B. U., Okada, H., Gronski, M. A., Bertram, E. M., Dawicki, W., Duncan, G. S., Bukczynski, J., Plyte, S., Elia, A., et al. (2003) · Nature Immunology · doi:10.1038/ni967 · Cited by 576 · cited 16×
“to increased IFN-g secretion as well as increased proliferation.(2,11,12) Increased T effector proliferation and inflammatory cytokine secretion could mean increased gut epithelial damage, as is supported by our finding of increased serum concentration of orally administered FITC-dextran.”
BackgroundResultInfluentialSelf-citationMurine B7-H3 is a negative regulator of T cells
Prasad, D. V. R., Nguyen, T., Li, Z., Yang, Y., Duong, J., Wang, Y., & Dong, C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.4.2500 · Cited by 368 · cited 3×
“We observed more IFN-g production in recipients of B7-H3 donor T cells, consistent with other studies, which showed that inhibiting B7-H3 led to increased IFN-g secretion as well as increased proliferation.(2,11,12) Increased gut epithelial damage could result from increased T effector proliferation, inflammatory cyto…”
BackgroundResult
Cited by
Acute Graft-versus-Host Disease — Biologic Process, Prevention, and Therapy
Zeiser, R., & Blazar, B. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1609337 · Cited by 1,296
Self-citationGlioma targeted therapy: insight into future of molecular approaches
Yang, K., Wu, Z., Zhang, H., Zhang, N., Wu, W., Wang, Z., Dai, Z., Zhang, X., Zhang, L., Peng, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01513-z · Cited by 704
Majzner, R. G., Theruvath, J. L., Nellan, A., Heitzeneder, S., Cui, Y., Mount, C. W., Rietberg, S. P., Linde, M. H., Xu, P., Rota, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0432 · Cited by 681
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy
Picarda, E., Ohaegbulam, K. C., & Zang, X. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2428 · Cited by 582
“Researchers from independent studies using either protein blockade or gene-knockout mice have reported that B7-H3 ameliorates graft-versus-host disease, prolongs cardiac allograft survival, reduces airway hypersensitivity, and delays EAE onset, especially by downregulating Th1 responses (8, 17, 18).”
BackgroundInhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
Andrews, L. P., Yano, H., & Vignali, D. A. A. (2019) · Nature Immunology · doi:10.1038/s41590-019-0512-0 · Cited by 543
Metadata
- Authors
- Veenstra, R. G., Flynn, R., Kreymborg, K., McDonald-Hyman, C., Saha, A., Taylor, P. A., Osborn, M. J., Panoskaltsis-Mortari, A., Schmitt-Graeff, A., Lieberknecht, E., Murphy, W. J., Serody, J. S., Munn, D. H., Freeman, G. J., Allison, J. P., Mak, T. W., van den Brink, M., Zeiser, R., & Blazar, B. R.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2015-03-26
- Volume
- 125
- Issue
- 21
- Pages
- 3335-3346
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1965507670
- Cited by
- 78
- References
- 2
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. https://app.cochat.ai/papers/10.1182/blood-2014-09-603357
- The paper
- Veenstra, R. G., Flynn, R., Kreymborg, K., McDonald-Hyman, C., Saha, A., Taylor, P. A., Osborn, M. J., Panoskaltsis-Mortari, A., Schmitt-Graeff, A., Lieberknecht, E., Murphy, W. J., Serody, J. S., Munn, D. H., Freeman, G. J., Allison, J. P., Mak, T. W., van den Brink, M., Zeiser, R., & Blazar, B. R. (2015). B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood. https://doi.org/10.1182/blood-2014-09-603357
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.